CTOs on the Move

Hospitals of Ontario Pension Plan

www.hoopp.com

 
Established in 1960, the Healthcare of Ontario Pension Plan (HOOPP) is a multi-employer defined benefit pension plan for Ontario`s hospital and community-based healthcare sector. We serve more than 435,000 members who provide valued healthcare services at more than 630 employers across the province. At HOOPP, we exist to provide a stable and reliable pension for our members that starts in retirement and is paid for life. As one of Canada`s largest and most respected pension plans, HOOPP`s net assets reached $103.7 billion at the end of 2022 and our funded status remained strong at 117%. HOOPP`s core values - professional, ...
  • Number of Employees: 250-1000
  • Annual Revenue: $250-500 Million
  • www.hoopp.com
  • 1 York Street Suite 1900
    Toronto, ON CAN M5J 0B6
  • Phone: 877.434.6677

Executives

Name Title Contact Details
Jennifer Williams
Chief Information Security Officer Profile

Similar Companies

Amryt Pharma

We are a commercial stage pharmaceutical company focused on developing and delivering innovative new treatments that help improve the lives of people with rare diseases.

ACM Global central laboratory

ACM Global central laboratory is a Rochester, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

CARBONDALE CLINIC AND SURGERY

CARBONDALE CLINIC AND SURGERY is a Carbondale, IL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Covance Labs

Covance Labs is a Princeton, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Juventas Therapeutics

Juventas Therapeutics is a private clinical-stage company developing novel therapies for ischemic cardiovascular disease. The company`s lead product` JVS-100` is a non-viral plasmid that encodes for stromal cell-derived factor-1 (SDF-1). SDF-1 has been shown to significantly increase end-organ function following tissue injury by promoting cell survival` recruiting endogenous stem cells to the damaged region` and promoting new blood vessel growth. The SDF-1 repair pathway is well conserved throughout end-organ systems providing the opportunity to impact a broad range of diseases. Target cardiovascular clinical indications address large markets with high unmet medical need and significant market potential. Juventas is currently enrolling multiple clinical trials to test therapy efficacy in heart failure and critical limb ischemia patients.